CytoMed Therapeutics (GDTC) Total Current Liabilities (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Total Current Liabilities for 5 consecutive years, with $547179.2 as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 19.98% to $547179.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $547179.2 through Dec 2025, up 19.98% year-over-year, with the annual reading at $551496.0 for FY2025, 24.2% up from the prior year.
  • Total Current Liabilities hit $547179.2 in Q4 2025 for CytoMed Therapeutics, up from $456044.1 in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $3.0 million in Q4 2022 to a low of $456044.1 in Q4 2024.
  • Historically, Total Current Liabilities has averaged $1.3 million across 5 years, with a median of $547179.2 in 2025.
  • Biggest five-year swings in Total Current Liabilities: soared 38.7% in 2022 and later plummeted 82.31% in 2023.
  • Year by year, Total Current Liabilities stood at $2.2 million in 2021, then surged by 38.7% to $3.0 million in 2022, then tumbled by 82.31% to $531034.3 in 2023, then fell by 14.12% to $456044.1 in 2024, then rose by 19.98% to $547179.2 in 2025.
  • Business Quant data shows Total Current Liabilities for GDTC at $547179.2 in Q4 2025, $456044.1 in Q4 2024, and $531034.3 in Q4 2023.